AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8603445
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) dose escalation (increased in monthly 25% steps if 75 mg/m2 was tolerated without cytopenias)
Trial: 8603445
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (without dose escalation)
Trial: 8603445
Drug: Escalated doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated doses of 6MP (30 children)
Trial: 8603445
Drug: 6MP dose
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MP dose escalation
Trial: 1577927
Drug: Intravaginal micronized
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal micronized progesterone (600 mg/day)
Trial: 1577927
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone in oil (50 mg/day)
Trial: 6375610
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phentermine resin (15 mg in the morning) and fenfluramine hydrochloride (30 mg before the evening meal)
Trial: 6375610
Drug: Fenfluramine hydrochloride
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine hydrochloride (20 mg three times a day)
Trial: 6375610
Drug: Phentermine resin
RxNorm normalized name: phentermine resin
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentermine resin (30 mg in the morning)
Trial: 26407273
Drug: Quadrivalent Influenza
RxNorm normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent Influenza Vaccine (QIV)
Trial: 26407273
Drug: Trivalent Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent Influenza Vaccine (TIV)
Trial: 24687003
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of segmental and prosody training
Trial: 22426247
Drug: Adaptive design
RxNorm normalized name: Designer Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive design with dose escalation and cohort expansion
Trial: 18042651
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion (5 pmol x kg(‐1) x min(‐1))
Trial: 15610655
Drug: Modern treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern treatment strategies including chemotherapy and radiotherapy
Trial: 15610655
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of chemotherapy doses or cycles
Trial: 15610655
Drug: Lower-radiation doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-radiation doses and smaller radiation field sizes
Trial: 15610655
Drug: More intense
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intense drug combinations for high-risk patients
Trial: 2044968
Drug: CAI treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAI treatments (MK-927 and MK-417)
Trial: 26749217
Drug: Buprenorphine 3
RxNorm normalized name: buprenorphine 356 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 3 mg with naltrexone (50 mg initiated 12 hours before and given every 12 hours for 4 doses)
Trial: 26749217
Drug: Open-label moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label moxifloxacin 400 mg with placebo naltrexone
Trial: 20813792
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (exact dosage not specified)
Trial: 15890561
Drug: Sitaxsentan (SITAX)
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sitaxsentan (SITAX) 100 mg orally once daily
Trial: 15890561
Drug: Sitaxsentan (SITAX)
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sitaxsentan (SITAX) 300 mg orally once daily
Trial: 9831969
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg loading dose of gentamicin or tobramycin (study group, n=4)
Trial: 9831969
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing regimen of 2 mg/kg loading dose followed by maintenance dose (control group, n=7)
Trial: 2530716
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis B vaccination
Trial: 2530716
Drug: Intramuscular hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hepatitis B vaccination
Trial: 21993710
Drug: Olmesartan (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (10-40 mg once daily)
Trial: 19624387
Drug: Quetiapine, 300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine, 300-600 mg/day
Trial: 9706913
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 2 g
Trial: 14741082
Drug: Aprotinin (AP)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (AP) high-dose according to Hammersmith
Trial: 3326574
Drug: Diary card
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diary card evaluation during PEP mask therapy
Trial: 22695489
Drug: Almorexant 1000
RxNorm normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Almorexant 1000 mg
Trial: 18798500
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 1.6 mg hypodermic injection, administered for 10 times
Trial: 8885956
Drug: t.i.d. dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. dosing
Trial: 8885956
Drug: b.i.d. dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. dosing
Trial: 8885956
Drug: t.i.d. and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. and titration conditions
Trial: 2063702
Drug: Household composition
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household composition and control over food selection/preparation
Trial: 2063702
Drug: Attendance at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attendance at treatment sessions
Trial: 6391932
Drug: diflunisal 1000
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diflunisal 1000 mg daily
Trial: 6391932
Drug: naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 750 mg daily
Trial: 30486711
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (guideline-directed therapy for HF)
Trial: 12077088
Drug: ISIS 2302
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 2302 (2 mg/kg intravenously three times a week for two weeks)
Trial: 12077088
Drug: ISIS 2302
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 2302 (2 mg/kg intravenously three times a week for four weeks)
Trial: 28237428
Drug: Adjunct slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct slow-release dexamethasone implant (Ozurdex; 0.7 mg)
Trial: 28237428
Drug: Adjunct slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct slow-release dexamethasone implant (Ozurdex)
Trial: 19414940
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg after each dialysis session for six months
Trial: 16519421
Drug: Pharmacological testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological testing (phentolamine, lidocaine, ketamine, thiopental, morphine, placebo)
Trial: 7848901
Drug: Guggulipid (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guggulipid (50 mg capsules twice daily for 24 weeks)
Trial: 7848901
Drug: Placebo (capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsules twice daily for 24 weeks)
Trial: 2903480
Drug: Surfactant (Curosurf)
RxNorm normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surfactant (Curosurf) 200 mg/kg
Trial: 4513355
Drug: Intermittent combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent combination chemotherapy as the only form of maintenance
Trial: 4513355
Drug: Weekly immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly immunotherapy in addition to chemotherapy
Trial: 12144580
Drug: rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg
Trial: 26365443
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of PTQXT
Trial: 26365443
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of PTQXT combined with external application of Chinese herbs
Trial: 26365443
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral antihistamine and placebo PTQXT pills with topical 1% mometasone furoate)
Trial: 26365443
Drug: Both Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Chinese herbal medicine-treated groups
Trial: 22289539
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg/kg intravenous bolus plus normal saline by intravenous infusion (K group, n = 30)
Trial: 22289539
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg/kg intravenous bolus plus remifentanil 0.15 μg/kg per min intravenous infusion (KR group, n = 30)
Trial: 19491658
Drug: Intravenous ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ATP (8‐10 h/week, maximum 50 microg/kg/min) for 8 weeks
Trial: 16941969
Drug: Oral anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-inflammatory analgesic medicine combined with acupuncture at Tiaokou (ST 38)
Trial: 16941969
Drug: Oral anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-inflammatory analgesic medicine
Trial: 12694150
Drug: Sufentanil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.3 micro g kg‐1
Trial: 10731509
Drug: High-calcium mineral
RxNorm normalized name: Mineral Oil (high Viscosity)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium mineral water (344 mg Ca/L)
Trial: 10731509
Drug: Low-calcium mineral
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calcium mineral water (<10 mg/L)
Trial: 9163027
Drug: Aciclovir (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir (treatment of choice for HSE)
Trial: 27372434
Drug: Lidocaine pre-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine pre-administration (1% lidocaine 30mg)
Trial: 20653641
Drug: Modafinil 400
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 400 mg daily for 3 days
Trial: 11236120
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose systemic methotrexate (50 mg/m2)
Trial: 31593081
Drug: Multicomponent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent therapy (MT group) consisting of health education, exercise, and cognitive-behavioral therapy during 12 weeks in 2-hourly weekly sessions.
Trial: 21569242
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 234 mg on Day 1
Trial: 21569242
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 156 mg on Day 8
Trial: 21569242
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 234 mg (Days 1 to 7)
Trial: 21569242
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 156 mg (Days 8 to 36)
Trial: 21569242
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 39 mg (Days 8 to 36)
Trial: 21569242
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 234 mg (Days 8 to 36)
Trial: 19355800
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg once daily
Trial: 19355800
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg once daily
Trial: 16573577
Drug: Alcohol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol plus energy drink (vodka 37.5% v/v and Red Bull 3.57 mL/kg)
Trial: 12771499
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART) with glass-ionomer
Trial: 9179367
Drug: Viscum album
RxNorm normalized name: Viscum album
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscum album agglutinin-I (10 and 1 ng/ml)
Trial: 9179367
Drug: Viscum album
RxNorm normalized name: Viscum album
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscum album agglutinin-I (lectin-enriched preparation)
Trial: 26501386
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intraoperative methylprednisolone
Trial: 20929999
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for 4 weeks
Trial: 16871570
Drug: TMA Assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMA Assay (LOD 9.6 IU/mL)
Trial: 12759295
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg, subcutaneously, twice weekly)
Trial: 11120531
Drug: Methotrexate infusion
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate infusion therapy (100 mg/m² intravenous bolus followed by 200 mg/m² infusion)
Trial: 11120531
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate, etoposide, and bleomycin)
Trial: 8211872
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 1.5 mg per day
Trial: 8211872
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 1.5 mg per day
Trial: 3102372
Drug: L-carnitine (4g/day)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (4g/day)
Trial: 3102372
Drug: L-carnitine (2g/day)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (2g/day)
Trial: 3102372
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-carnitine)
Trial: 30975570
Drug: PHiD‐CV/dPly/PhtD (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV/dPly/PhtD (10 or 30 µg of each protein) with 3+0 schedule (2‐3‐4 months)
Trial: 30975570
Drug: PHiD‐CV/dPly/PhtD (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV/dPly/PhtD (30 µg of each protein) with 2+1 schedule (2‐4‐9 months)
Trial: 30975570
Drug: DTPw‐HBV/Hib, OPV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw‐HBV/Hib, OPV, measles, yellow fever vaccines co-administered with pneumococcal proteins
Trial: 30975570
Drug: Co-administered vaccines
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administered vaccines
Trial: 26649812
Drug: Focused Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused Enhanced Cognitive Behavior Therapy (CBT‐Ef)
Trial: 26649812
Drug: Broad Enhanced
RxNorm normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad Enhanced Cognitive Behavior Therapy (CBT‐Eb)
Trial: 16151286
Drug: Single-shot fascia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot fascia iliaca compartment block (FICB) with ropivacaine 0.2% for bolus and saline for infusion
Trial: 16151286
Drug: Continuous fascia
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous fascia iliaca compartment block (FICB) with ropivacaine 0.2% for bolus and infusion
Trial: 16151286
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with saline for both bolus and infusion
Trial: 10533689
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam administration
Trial: 10533689
Drug: Teaching at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching at 3 hours after midazolam administration
Trial: 9084546
Drug: Midazolam (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.06 mg/kg) and Propofol (20 mg/5 s) for induction; Propofol (8 mg/kg/hr) for maintenance
Trial: 9084546
Drug: Propofol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (20 mg/5 s) for induction; Propofol (10 mg/kg/h) for maintenance
Trial: 17136042
Drug: cholesterol-reducing diet
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cholesterol-reducing diet (high in plant sterols 1.0 g/1000 kcal, soy protein 22.5 g/1000 kcal, viscous fibers 10 g/1000 kcal, almonds 23 g/1000 kcal)
Trial: 7706804
Drug: Cidofovir alone
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir alone at doses of 0.5, 1.0, 3.0, or 10.0 mg/kg/week (20 patients)
Trial: 7706804
Drug: Cidofovir at
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir at 3.0, 5.0, or 7.5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)
Trial: 27876342
Drug: Ciprofibrate 100
RxNorm normalized name: ciprofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate 100 mg/d for 12 weeks
Trial: 27876342
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids 1800 mg/d for 12 weeks
Trial: 17694045
Drug: Discontinued warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued warfarin (group 1)
Trial: 17694045
Drug: Suturing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suturing and discontinued warfarin (group 3)
Trial: 17694045
Drug: Continued warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued warfarin (group 2)
Trial: 17694045
Drug: Suturing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suturing and continued warfarin (group 4)
Trial: 30077809
Drug: Symbicort® pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) with AeroChamber Plus® Flow‐Vu® spacer
Trial: 30077809
Drug: Symbicort® pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort® pMDI 160/4.5 μg/actuation (2 actuations) without spacer